4.6 Article

Chlorhexidine oral rinses for symptomatic COPD: a randomised, blind, placebo-controlled preliminary study

期刊

BMJ OPEN
卷 11, 期 12, 页码 -

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/bmjopen-2021-050271

关键词

-

资金

  1. Flight Attendant Medical Research Institute (FAMRI) Clinical Innovator Award [150014]
  2. Department of Veterans Affairs Office of Research and Development [1IK2CX001095]

向作者/读者索取更多资源

The study found that using chlorhexidine oral rinses did not significantly decrease the microbiota biomass in the oral and sputum samples, but did reduce the diversity of microbiota in these samples and improved the quality of life related to respiratory health.
Objectives Determine the effect of twice-daily chlorhexidine oral rinses on oral and lung microbiota biomass and respiratory symptoms. Setting Single centre. Participants Participants were aged 40-85 with chronic obstructive pulmonary disease (COPD) and chronic productive cough or COPD exacerbation within the last year. Exclusions included antibiotics in the previous 2 months and/or those with less than four teeth. Forty-four participants were recruited and 40 completed the study. Intervention Participants were randomised 1:1 to twice-daily 0.12% chlorhexidine oral rinses versus placebo for 2 months along with daily diaries. St. George's Respiratory Questionnaire (SGRQ), blood tests, oral rinse and induced sputum were collected at randomisation and the final visit. Primary and secondary outcomes Primary outcome was a change in oral and sputum microbiota biomass. Secondary outcomes included: sputum and oral microbiota Shannon and Simpson diversity and taxonomy; inflammatory markers; Breathlessness, Cough and Sputum Scale and SGRQ scores. Results Neither the oral microbiota nor the sputum microbiota biomass decreased significantly in those using chlorhexidine compared with placebo (oral microbiota mean log(10) difference (SE)=-0.103 (0.23), 95% CI -0.59 to 0.38, p=0.665; sputum microbiota 0.80 (0.46), 95% CI -0.15 to 1.75, p=0.096). Chlorhexidine decreased both oral and sputum microbiota alpha (Shannon) diversity (linear regression estimate (SE) oral: -0.349 (0.091), p=0.001; sputum -0.622 (0.169), p=0.001). Chlorhexidine use did not decrease systemic inflammatory markers compared with placebo (C reactive protein (chlorhexidine 1.8 +/- 7.5 vs placebo 0.4 +/- 6.8, p=0.467), fibrinogen (22.5 +/- 77.8 vs 10.0 +/- 77.0, p=0.406) or leucocytes (0.2 +/- 1.8 vs 0.5 +/- 1.8, p=0.560)). Chlorhexidine use decreased SGRQ scores compared with placebo (chlorhexidine -4.7 +/- 8.0 vs placebo 1.7 +/- 8.9, p=0.032). Conclusions We did not detect a significant difference in microbiota biomass due to chlorhexidine use. Chlorhexidine decreased oral and sputum microbiota alpha diversity and improved respiratory health-related quality of life compared with placebo.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据